Rep. Dwight Evans discloses stock sales lagging S&P 500 on 30-day basis
Embed this grade
Why this grade: Claims match BlindTrust analysis of public STOCK Act filings showing eight scored trades with negative alpha versus S&P 500; minor gaps include updated trade count and small sample size caveats
Why this lean: Satirical framing highlights underperformance by a Democratic member on Ways and Means Health subcommittee without equivalent counter-examples or broader context on market timing difficulty
Disagree with this grade or political lean?
Tell us why. Your note is reprocessed through the same grading logic; if the output is still off the report is removed, and if it holds up it stays.
Topics in this report
Summary
The clip from BlindTrust presents Rep. Dwight Evans, D-PA, as having sold nine stocks with all underperforming the market on a forward basis. It highlights a May 7 sale of Thermo Fisher Scientific and notes his assignment to the Health subcommittee. The tone is mocking, with a repetitive chant-like close.
BlindTrust derives its scores from periodic transaction reports filed under the STOCK Act. It compares each trade's 30-day performance to the S&P 500 and flags committee overlaps. The segment draws on eight prior scored trades with a mean alpha of -5.7%.
Editorial Assessment
The underlying data from public disclosures holds up and is accurately summarized. Viewers miss the small dollar amounts involved ($1K-$15K brackets), the limited sample of eight trades, and the site's own acknowledgment that markets are difficult to time. The video emphasizes the Thermo Fisher committee overlap while omitting that no vote-trade linkage is claimed. Framing treats consistent underperformance as noteworthy without discussing how often random selling might produce similar results. Overall the piece is data-driven but selective in emphasis.
Key Moments
Dwight Evans sold nine stocks; all lost to the market
BlindTrust analysis of eight scored trades shows 0 positive alpha vs S&P 500; video rounds to nine
Sold Thermo Fisher on May 7; stock beat market by eight points afterward
Filing confirms May 7, 2026 partial sale of TMO; BlindTrust records -7.8% alpha (stock outperformed index)
Evans sits on Health subcommittee
Official House records list him on Ways and Means Subcommittee on Health
Worst trade lost fourteen points
Matches Micron Technology (MU) March 2026 sale at -14.1% alpha per BlindTrust
Notable Concerns
- Satirical tone may overstate significance of small-sample results